Analysts expect Nanobiotix to report Q2 2026 revenue of $1.73 million and a net loss of $0.29 per share, with the stock currently trading at approximately $33.45 compared to a consensus price target of $54.13.
The primary story for investors is the clinical advancement of the lead candidate NBTXR3, particularly the pivotal Phase 3 NANORAY-312 study for head and neck cancer.
Recent developments include FDA clearance for a protocol amendment that streamlines the study's path to final analysis, potentially accelerating the regulatory timeline. Furthermore, the company’s cash runway has been extended into 2029 following a successful capital raise of approximately €86 million.